USPTO serial 79295828
PRÉNUMBRA
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Oct 5, 2021
- Examiner
- WELLS, KELLEY L
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with PRÉNUMBRA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceuticals for the prevention and treatment of autoimmune, inflammatory and skin diseases or disorders, for the treatment of viral, metabolic, endocrine, musculoskeletal, ophthalmic, cardiovascular, cerebrovascular, cardiopulmonary, genitourinary, oncological, hepatological, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders and for the prevention and treatment of genetic diseases and disorders; hemodynamic, vasoactive and anti-oncotic pharmaceuticals; Pharmaceutical drugs for the prevention and treatment of autoimmune, inflammatory and skin diseases or disorders, for the treatment of viral, metabolic, endocrine, musculoskeletal, ophthalmic, cardiovascular, cerebrovascular, cardiopulmonary, genitourinary, oncological, hepatological, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders and for the prevention and treatment of genetic diseases and disorders; hemodynamic, vasoactive and anti-oncotic pharmaceutical drugs; Pharmaceutical preparations for the prevention and treatment of autoimmune, inflammatory and skin diseases or disorders, for the treatment of viral, metabolic, endocrine, musculoskeletal, ophthalmic, cardiovascular, cerebrovascular, cardiopulmonary, genitourinary, oncological, hepatological, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders, for the treatment of vascular anomalies and oedema and for the prevention and treatment of genetic diseases and disorders; hemodynamic, vasoactive and anti-oncotic pharmaceutical preparations; Pharmaceuticals used for cerebrovascular accidents in the nature of strokes; Cardiovascular drug preparations; Cardiovascular pharmaceuticals; cardiovascular pharmaceutical preparations; Cardiovascular medicinal agents for medical purposes; Cardiovascular drugs used in treating shocks; cardiovascular drugs used in myocardial infarctions; cardiovascular drugs used in treating arrhythmias; cardiovascular drugs used in angina pectoris; pharmaceutical preparations for the treatment of cardiovascular disease; cardiovascular drugs used in treating congestive heart failure (CHF); Pharmaceutical preparations, preferably based on analogues of melanocyte stimulating hormone (MSH), in particular afamelanotide for use in treating skin and skin relating conditions and disorders; Medicated sun tanning preparations for pharmaceutical purposes, preferably based on analogues of melanocyte stimulating hormone (MSH), in particular afamelanotide; Pharmaceutical preparations for skin care; pharmaceutical preparations for treating skin disorders; Medicated dermatological preparations; Dermatological pharmaceutical substances; Dermatological pharmaceutical products, namely, preparations for treating or preventing skin disorders; Medicinal creams for the protection of the skin; Medicated skin care creams for medical use for treating or preventing skin disorders; Medicated skin care preparations for medical use; Medicated skin creams and lotions; medicated creams for application after exposure to the sun; pharmaceutical skin lotions; preparations for cleansing the skin for medical use; Chemical and biological preparations, substances, reagents and compounds for the delivery and storage of a wide range of pharmaceuticals which are preferably based on analogues of melanocyte stimulating hormone (MSH), in particular afamelanotide; Afamelanotide hormone in aqueous and gel formulations | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Apr 18, 2022 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Mar 24, 2022 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Mar 24, 2022 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Jan 5, 2022 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Oct 5, 2021 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jul 20, 2021 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jul 20, 2021 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jul 19, 2021 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Jun 30, 2021 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jun 30, 2021 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Jun 30, 2021 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jun 17, 2021 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jun 16, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 16, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 16, 2021 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 11, 2021 | RFNT | REFUSAL PROCESSED BY IB | — |
| Dec 21, 2020 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Dec 21, 2020 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Dec 14, 2020 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Dec 13, 2020 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 6, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 23, 2020 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Oct 19, 2020 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 15, 2020 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |